Public Company News
Eoptolink Releases OSFP 1.6T DR8 and 2FR4 Series Transceivers for AI/ML Clusters and Cloud Datacenter Networks
CHENGDU, China, Sept. 20, 2024 /PRNewswire/ -- Eoptolink Technology Inc., Ltd. (SZSE: 300502), a leading innovator and provider of advanced optical transceiver solutions, announces the release of its OSFP 1.6T DR8/DR8-2 and 2xFR4 transceivers enabling the next generation high bandwidth networks f...
2024-09-20 13:30
2826
Xiao-I Corporation Renews and Expands Partnership with Inner Mongolia Yili, Transitioning to Subscription-Based Model for AI Services
SHANGHAI, Sept. 19, 2024 /PRNewswire/ -- Xiao-I Corporation (NASDAQ: AIXI) ("Xiao-I" or the "Company"), a leading artificial intelligence company, today announced the renewal of its contract with Inner Mongolia Yili Industrial Group Co., Ltd. ("Yili") (A Share:600887). This renewal continues a lo...
2024-09-19 21:45
3344
WiMi Developed a Blockchain-Based Integrated Architecture for Security Maintenance in Cloud Computing
BEIJING, Sept. 19, 2024 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that it integrated cloud computing and blockchain technology, and developed a blockchain-based integra...
2024-09-19 21:30
5825
Nuzee, Inc. Announces Endorsement Agreement Between Macanuoli and Five Sports Champions
VISTA, Calif., Sept. 19, 2024 /PRNewswire/ -- NUZEE, INC., ("NUZEE"or the "Company") (NASDAQ：NUZE) a Company with a heritage in specialty coffee and an emerging business in broader consumer food and beverage products, today announced that the Company has signed an endorsement agreement with five ...
2024-09-19 20:30
5959
"BLEACH Soul Puzzle" Launches Worldwide on September 24, 2024 as the First Puzzle Game Based on the BLEACH TV Animation Series
TOKYO, Sept. 19, 2024 /PRNewswire/ -- KLab Inc., a leader in online mobile games, announced that the first puzzle game based on the hit TV animation series BLEACH,BLEACH Soul Puzzle, is set for a worldwide release on Tuesday, September 24, 2024. (Support is provided for English and Japanese.) See...
2024-09-19 14:10
2840
Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC
SHANGHAI, Sept. 18, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety and Efficacy of Irpagratinib (ABSK011) in advanced hepatocell...
2024-09-19 09:00
6465
Uxin to Report First Quarter Fiscal Year 2025 Financial Results on September 23, 2024
BEIJING, Sept. 18, 2024 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN),China's leading used car retailer, today announced that it will release its unaudited financial results for the first quarter of fiscal year 2025 endedJune 30, 2024, before the U.S. market opens on Septe...
2024-09-18 17:00
4616
Maitong Sunshine Cultural Begins Trading on the OTC Markets
NEW YORK, Sept. 18, 2024 /PRNewswire/ -- Maitong Sunshine Cultural Development Co., Limited (OTC Markets: MGSD, the "Company") today announced that the Company begins trading on the OTC Markets. The Company is a professional enterprise that provides cultural and tourism services with distinctive ...
2024-09-18 16:30
4355
Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI
TAIPEI and SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), , a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that an Investigational New Drug (IND) application for Pidnarulex ...
2024-09-18 10:06
3068
Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD
SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Hyundai Bioscience USA announced that it has signed an MOU with theUniversity of California San Diego (UCSD) to conduct an investigator-initiated trial to evaluate the efficacy of Xafty®, a niclosamide-based antiviral developed by its Korean headquarters,...
2024-09-18 09:26
3834
XCharge, Asia Green Fund's Portfolio, Successfully Listed on Nasdaq
BEIJING, Sept. 14, 2024 /PRNewswire/ -- XCHG Limited (XCHARGE) (NASDAQ: XCH) announced the pricing of its initial public offering. XCharge, founded in 2015, is a global leader in integrated EV charging solutions, focusing on Innovative New Energy Technologies and Sustainable Development . The Co...
2024-09-18 09:22
3135
Mega Matrix Announces That the Short Drama "Revenge Beyond the Grave", Will Be Released on September 18 at FlexTV
PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Mega Matrix Corp. ("MPU" or the "Company") (NYSE American: MPU), today announced that it will launch its revenge short drama "Revenge Beyond the Grave" onSeptember 18th at FlexTV. This is no ordinary tale of vengeance, as it delves deeper into t...
2024-09-18 00:49
3032
Datasea's New 5G AI Multimodal Agreements Have Already Generated $9.0 Million of 5G-AI Services
Agreements Boost Fiscal 2025 Revenue and Expand Datasea's 5G Application Market Positioning inChina BEIJING, Sept. 17, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based company focused on innovative high-tech acoustics and 5G-Artificial Intelligence ("A...
2024-09-17 21:45
2705
Subgroup Analysis from Pivotal WU-KONG1B Study Exhibits Robust Efficacy of Sunvozertinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations Across Different Baseline Characteristics
Results of subgroup analysis from the pivotal WU-KONG1B study in relapsed or refractory NSCLC with EGFR exon20ins presented at ESMO 2024 * Sunvozertinib demonstrated promising anti-tumor efficacy, regardless of EGFR exon20ins region classification, race, region, baseline brain metastasis, prio...
2024-09-17 15:47
3018
Harvard Business School examines DBS' AI strategy and implementation in its first case study focusing on AI in an Asian bank
Authored by Feng Zhu, HBS Professor of Business Administration, the case highlights the bank's use of AI and takeaways for companies navigating technological change SINGAPORE, Sept. 16, 2024 /PRNewswire/ -- Harvard Business School (HBS) has published a case study on DBS' strategy towards Artific...
2024-09-16 22:00
4492
Intelligent Living Application Group Inc. Regains Compliance with Nasdaq's Minimum Bid Price Rule
HONG KONG, Sept. 16, 2024 /PRNewswire/ -- Intelligent Living Application Group
Inc. (NASDAQ:ILAG
2024-09-16 21:00
5779
Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment
BEIJING, Sept. 16, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that Guangzhou Concord Cancer Center ("Guangzhou H...
2024-09-16 20:00
3281
Game-Changing Lidar OT128 from Hesai Unveiled at IAA Transportation, Accelerating Autonomous Vehicles' Commercial Deployment
HANNOVER, Germany, Sept. 16, 2024 /PRNewswire/ -- Hesai Technology (Nasdaq: HSAI), the global leader in lidar technology, is launching its powerful new lidar solution OT128 atEurope's biggest commercial vehicle trade fair IAA Transportation inHannover (booth location: Hall 12, #C71). Hesai's OT12...
2024-09-16 20:00
2429
Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment
NANJING, China, Sept. 16, 2024 /PRNewswire/ -- Vazyme (688105.SH), a leading life science technology company, significantly contributed to groundbreaking research published in Science Magazine through its innovative products. The study, which focuses on how mutant IDH1 inhibition activates tumor ...
2024-09-16 19:00
2918
Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024
* In patients with non-small cell lung cancer (NSCLC) or melanoma who had acquired resistance to checkpoint inhibitors (CPIs), ATN-037 in combination with KEYTRUDA®(pembrolizumab) demonstrated an overall response rate (ORR) of 21.1% and a disease control rate (DCR) of 89.5%. * Data from the...
2024-09-16 18:00
3200
Week's Top Stories
Most Reposted
DBS crowned Southeast Asia's most valuable brand in Kantar BrandZ 2026 ranking
[Picked up by 303 media titles]
2026-07-15 12:00
A New Chapter Beckons: Four Seasons Resorts of Asia Celebrates Parenthood with Babymoon Offerings
[Picked up by 295 media titles]
2026-07-10 13:30
Gnomey Hollows Opens at PARKROYAL COLLECTION Marina Bay, Singapore, Extending the Hotel's Gnome-Themed Family Experience
[Picked up by 289 media titles]
2026-07-13 11:42
NCS launches enterprise AI platforms and products; deepens partnerships to accelerate AI-driven business transformation
[Picked up by 288 media titles]
2026-07-09 08:00Tetra Pak Introduces Industry-first Carton Packaging for Shelf-stable Tuna to Support Southeast Asia's Growing Tuna Industry
[Picked up by 285 media titles]
2026-07-13 10:00
Most Read
NYSE Content Update: Samos Energy Acquisition to Make NYSE Debut
2026-07-10 21:04
9103
Elong Power Holding Limited Announces Pricing of US$6.6 Million Public Offering
2026-07-10 20:30
8934
Amcor expands packaging facility in China
2026-07-09 22:48
8241
